[go: up one dir, main page]

WO2008147245A3 - Controlled release proxodolol pharmaceutical composition - Google Patents

Controlled release proxodolol pharmaceutical composition Download PDF

Info

Publication number
WO2008147245A3
WO2008147245A3 PCT/RU2007/000619 RU2007000619W WO2008147245A3 WO 2008147245 A3 WO2008147245 A3 WO 2008147245A3 RU 2007000619 W RU2007000619 W RU 2007000619W WO 2008147245 A3 WO2008147245 A3 WO 2008147245A3
Authority
WO
WIPO (PCT)
Prior art keywords
proxodolol
controlled release
pharmaceutically acceptable
active ingredient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2007/000619
Other languages
French (fr)
Russian (ru)
Other versions
WO2008147245A2 (en
Inventor
Sergei Danilovich Juzhakov
Robert Georgievich Glushkov
Viktor Vladimirovich Chistyakov
Natalya Vyacheslavovna Aristovskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Borovichsky Kombinat Ogneuporov OAO
Original Assignee
Borovichsky Kombinat Ogneuporov OAO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Borovichsky Kombinat Ogneuporov OAO filed Critical Borovichsky Kombinat Ogneuporov OAO
Publication of WO2008147245A2 publication Critical patent/WO2008147245A2/en
Publication of WO2008147245A3 publication Critical patent/WO2008147245A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to medicine, in particular to pharmaceutic. A novel preparation exhibiting stable kinetic characteristics relating to delivery of an active substance is disclosed. The controlled release proxodolol pharmaceutical forms can be effectively and easily produced using a mixture of one or more expanding or gel-forming components, an active ingredient and a pharmaceutically acceptable filler. In the preferred embodiment, a preparation in the form of tablets containing proxodolol in a quantity of 120 mg, hypromellose and pharmaceutically acceptable fillers, for example microcristalline cellulose, calcium stearate and aerosil, is used. The novel pharmaceutical forms with a suitable proxodolol release make it possible to reduce the number of every day medications, whilst the concentration of the active ingredient remains constant within a therapeutic dose.
PCT/RU2007/000619 2007-06-01 2007-11-13 Controlled release proxodolol pharmaceutical composition Ceased WO2008147245A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2007120431/15A RU2356532C2 (en) 2007-06-01 2007-06-01 Controlled-release pharmaceutical proxodolol composition
RU2007120431 2007-06-01

Publications (2)

Publication Number Publication Date
WO2008147245A2 WO2008147245A2 (en) 2008-12-04
WO2008147245A3 true WO2008147245A3 (en) 2009-06-04

Family

ID=40075688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000619 Ceased WO2008147245A2 (en) 2007-06-01 2007-11-13 Controlled release proxodolol pharmaceutical composition

Country Status (2)

Country Link
RU (1) RU2356532C2 (en)
WO (1) WO2008147245A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9459187B2 (en) 2011-03-04 2016-10-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014070A1 (en) * 1994-11-02 1996-05-17 Janssen Pharmaceutica N.V. Cisapride extended release oral compositions
WO2000021525A2 (en) * 1998-10-14 2000-04-20 Novartis Ag Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0227948D0 (en) * 2002-11-29 2003-01-08 Cipla Ltd Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines
RU2248206C1 (en) * 2003-06-30 2005-03-20 Федеральное государственное унитарное предприятие "Центр по химии лекарственных средств" (ФГУП ЦХЛС-ВНИХФИ) Medicinal preparation for treatment of chronic cardiac insufficiency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014070A1 (en) * 1994-11-02 1996-05-17 Janssen Pharmaceutica N.V. Cisapride extended release oral compositions
WO2000021525A2 (en) * 1998-10-14 2000-04-20 Novartis Ag Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Also Published As

Publication number Publication date
WO2008147245A2 (en) 2008-12-04
RU2007120431A (en) 2008-12-10
RU2356532C2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
JP2008543767A5 (en)
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
RU2333745C2 (en) Compositions with controlled liberation
EA200801926A1 (en) TABLETS OF PARACETAMOL WITH FAST DELIVERY
UA116334C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
FI2508188T3 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
JP2016104812A (en) Solid preparation containing loxoprofen sodium and tranexamic acid
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
BRPI0513598A (en) enteric release coated tablet dosage forms
WO2003045305A3 (en) Acetaminophen compositions
WO2008147245A3 (en) Controlled release proxodolol pharmaceutical composition
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
JP4138209B2 (en) Pravastatin-containing composition
DE602005008128D1 (en) Cytisine-containing drug
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
MX2008001532A (en) Pharmaceutical composition containing indometacin and/or acemetacin.
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
Shetty et al. Design and evaluation of sustained release matrix tablets of etodolac
WO2015069140A1 (en) Pharmaceutical composition in tablet form and method for the production thereof
JP6112765B2 (en) Solid preparation containing loxoprofen sodium and dl-methylephedrine hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861043

Country of ref document: EP

Kind code of ref document: A2